Syringes Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032
The Global Syringes Market was valued at USD 19.6 billion in 2023, with projections indicating a 10.9% CAGR from 2024 to 2032. Syringes, vital medical devices for fluid injection and withdrawal, consist of a barrel, plunger, and needle or nozzle for precise fluid control.
Growth in this market is driven by an aging population and an increase in chronic health conditions, which elevate the demand for safe, reliable injection devices. Additionally, the rise in home healthcare adoption supports syringe use as patients seek more convenient and affordable treatment solutions beyond clinical settings.
The market is segmented by preparation into ready-to-use (RTU) and ready-to-sterilize (RTS) syringes. The RTU segment leads the market, with an anticipated 11.1% CAGR, owing to its convenience for healthcare providers and patients. Often prefilled with medication, RTU syringes simplify administration, minimize dosage errors, and reduce contamination risk. Their design promotes compliance, particularly in chronic disease management, and is increasingly favored in home healthcare due to the ease of self-administration.
By application, the market is categorized into small molecules, diagnostics, and biologics, with biologics holding a 54.7% share in 2023. This segment’s strength stems from the growing demand for biologic drugs targeting chronic and autoimmune conditions, which require precise delivery methods. The shift toward personalized medicine further underscores the need for efficient delivery systems, solidifying biologics' market dominance.
In North America, the U.S. leads with a CAGR of 10.6%, driven by advanced healthcare infrastructure, strong R&D efforts, and high demand for medical devices. The U.S. focus on innovation has produced advanced syringe technologies, including safety-engineered and prefilled options that enhance patient safety and treatment effectiveness. Rising chronic diseases and vaccination initiatives further stimulate market growth.
Growth in this market is driven by an aging population and an increase in chronic health conditions, which elevate the demand for safe, reliable injection devices. Additionally, the rise in home healthcare adoption supports syringe use as patients seek more convenient and affordable treatment solutions beyond clinical settings.
The market is segmented by preparation into ready-to-use (RTU) and ready-to-sterilize (RTS) syringes. The RTU segment leads the market, with an anticipated 11.1% CAGR, owing to its convenience for healthcare providers and patients. Often prefilled with medication, RTU syringes simplify administration, minimize dosage errors, and reduce contamination risk. Their design promotes compliance, particularly in chronic disease management, and is increasingly favored in home healthcare due to the ease of self-administration.
By application, the market is categorized into small molecules, diagnostics, and biologics, with biologics holding a 54.7% share in 2023. This segment’s strength stems from the growing demand for biologic drugs targeting chronic and autoimmune conditions, which require precise delivery methods. The shift toward personalized medicine further underscores the need for efficient delivery systems, solidifying biologics' market dominance.
In North America, the U.S. leads with a CAGR of 10.6%, driven by advanced healthcare infrastructure, strong R&D efforts, and high demand for medical devices. The U.S. focus on innovation has produced advanced syringe technologies, including safety-engineered and prefilled options that enhance patient safety and treatment effectiveness. Rising chronic diseases and vaccination initiatives further stimulate market growth.
Report Content
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising chronic diseases and geriatric population
3.2.1.2 Increasing vaccination initiatives
3.2.1.3 Growing technology advancement focusing on patient safety
3.2.1.4 Rise in biologics and biosimilars research activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 High risk of needlestick injuries
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter’s analysis
3.7 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PREPARATION, 2021 – 2032 ($ MN AND UNITS)
5.1 Key trends
5.2 Ready to use (RTU)
5.3 Ready to sterilize (RTS)
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN AND UNITS)
6.1 Key trends
6.2 Small molecules
6.3 Biologics
6.4 Diagnostics
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MATERIAL, 2021 – 2032 ($ MN AND UNITS)
7.1 Key trends
7.2 Glass
7.3 Plastic/ polymers
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY SIZE, 2021 – 2032 ($ MN AND UNITS)
8.1 Key trends
8.2 <1 ml
8.3 1 ml - 2 ml
8.4 3 ml - 5 ml
8.5 6 ml - 10 ml
8.6 10 - 20 ml
8.7 20 - 30 ml
8.8 >30 ml
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 ($ MN AND UNITS)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Pharma & biotech companies
9.4 Contract development and manufacturing organizations (CDMOs)
9.5 Diagnostic laboratories
9.6 Other end users
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN AND UNITS)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Becton, Dickinson and Company (BD)
11.2 Cardinal Health
11.3 Corning
11.4 Daikyo Seiko
11.5 DWK Life Sciences
11.6 Gerresheimer AG
11.7 ICU Medical
11.8 Mitsubishi Gas Chemical Company
11.9 Nipro
11.10 SCHOTT Pharma (SCHOTT Group)
11.11 Shandong Province Medicinal Glass
11.12 SHIOTANI GLASS
11.13 Terumo
11.14 Weigao Group
11.15 West Pharmaceutical Services
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising chronic diseases and geriatric population
3.2.1.2 Increasing vaccination initiatives
3.2.1.3 Growing technology advancement focusing on patient safety
3.2.1.4 Rise in biologics and biosimilars research activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 High risk of needlestick injuries
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter’s analysis
3.7 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PREPARATION, 2021 – 2032 ($ MN AND UNITS)
5.1 Key trends
5.2 Ready to use (RTU)
5.3 Ready to sterilize (RTS)
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN AND UNITS)
6.1 Key trends
6.2 Small molecules
6.3 Biologics
6.4 Diagnostics
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MATERIAL, 2021 – 2032 ($ MN AND UNITS)
7.1 Key trends
7.2 Glass
7.3 Plastic/ polymers
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY SIZE, 2021 – 2032 ($ MN AND UNITS)
8.1 Key trends
8.2 <1 ml
8.3 1 ml - 2 ml
8.4 3 ml - 5 ml
8.5 6 ml - 10 ml
8.6 10 - 20 ml
8.7 20 - 30 ml
8.8 >30 ml
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 ($ MN AND UNITS)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Pharma & biotech companies
9.4 Contract development and manufacturing organizations (CDMOs)
9.5 Diagnostic laboratories
9.6 Other end users
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN AND UNITS)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Becton, Dickinson and Company (BD)
11.2 Cardinal Health
11.3 Corning
11.4 Daikyo Seiko
11.5 DWK Life Sciences
11.6 Gerresheimer AG
11.7 ICU Medical
11.8 Mitsubishi Gas Chemical Company
11.9 Nipro
11.10 SCHOTT Pharma (SCHOTT Group)
11.11 Shandong Province Medicinal Glass
11.12 SHIOTANI GLASS
11.13 Terumo
11.14 Weigao Group
11.15 West Pharmaceutical Services
